Abstract | BACKGROUND: METHODS: RESULTS: After six cycles of treatment, a significant decrease in uterine, leiomyoma, and non- leiomyoma sizes was detected in both groups in comparison with baseline. At the same time, no significant difference in uterine and non- leiomyoma sizes was observed between the groups. Leiomyoma sizes were significantly (P < 0.05) lower in group A than in group B. No difference was observed in leiomyoma-related symptoms between groups throughout the study period. CONCLUSIONS:
|
Authors | Stefano Palomba, Tiziana Russo, Francesco Orio Jr, Libuse Tauchmanovà, Errico Zupi, Pier Luigi Benedetti Panici, Carmine Nappi, Annamaria Colao, Gaetano Lombardi, Fulvio Zullo |
Journal | Human reproduction (Oxford, England)
(Hum Reprod)
Vol. 17
Issue 12
Pg. 3213-9
(Dec 2002)
ISSN: 0268-1161 [Print] England |
PMID | 12456626
(Publication Type: Clinical Trial, Journal Article, Randomized Controlled Trial)
|
Chemical References |
- Delayed-Action Preparations
- Placebos
- Selective Estrogen Receptor Modulators
- Raloxifene Hydrochloride
- Leuprolide
|
Topics |
- Delayed-Action Preparations
- Female
- Hot Flashes
- Humans
- Leiomyoma
(diagnostic imaging, drug therapy)
- Leuprolide
(administration & dosage, adverse effects)
- Menorrhagia
- Pain
- Patient Dropouts
- Placebos
- Premenopause
- Prospective Studies
- Raloxifene Hydrochloride
(administration & dosage, adverse effects)
- Selective Estrogen Receptor Modulators
(administration & dosage, adverse effects)
- Ultrasonography
- Uterine Neoplasms
(diagnostic imaging, drug therapy)
|